Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Position Reduced by Atria Wealth Solutions Inc.

Atria Wealth Solutions Inc. decreased its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 25.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,212 shares of the pharmaceutical company’s stock after selling 2,523 shares during the period. Atria Wealth Solutions Inc.’s holdings in Vertex Pharmaceuticals were worth $2,904,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Highline Wealth Partners LLC acquired a new position in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $27,000. Dunhill Financial LLC increased its holdings in shares of Vertex Pharmaceuticals by 70.6% in the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 24 shares during the period. Brown Lisle Cummings Inc. acquired a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at about $30,000. Legacy Investment Solutions LLC acquired a new position in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $33,000. Finally, Truvestments Capital LLC acquired a new position in shares of Vertex Pharmaceuticals in the 3rd quarter valued at about $35,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 244 shares of the firm’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total value of $111,034.64. Following the completion of the sale, the executive vice president now directly owns 67,695 shares in the company, valued at approximately $30,805,286.70. This trade represents a 0.36 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on VRTX shares. Piper Sandler dropped their price objective on Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating on the stock in a report on Monday, January 27th. UBS Group increased their price objective on Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. dropped their price objective on Vertex Pharmaceuticals from $503.00 to $500.00 and set an “overweight” rating on the stock in a report on Monday, December 23rd. William Blair reiterated an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Friday, January 31st. Finally, Stifel Nicolaus increased their price target on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the company a “hold” rating in a report on Monday, December 16th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus price target of $505.61.

Vertex Pharmaceuticals Stock Up 0.8 %

Shares of NASDAQ VRTX opened at $484.24 on Friday. The stock has a market cap of $124.35 billion, a PE ratio of -220.11, a PEG ratio of 2.07 and a beta of 0.41. The business has a fifty day moving average of $436.05 and a two-hundred day moving average of $460.70. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. As a group, equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.58 earnings per share for the current fiscal year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.